SBTX — Skinbiotherapeutics Income Statement
0.000.00%
Last trade - 00:00
- £28.54m
- £25.80m
- £0.13m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.075 | 0.132 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 0.045 | 0.085 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1.36 | 1.62 | 1.5 | 3.06 | 3.13 |
Operating Profit | -1.36 | -1.62 | -1.5 | -2.98 | -3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.36 | -1.62 | -1.5 | -2.99 | -3.01 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.15 | -1.5 | -1.43 | -2.79 | -2.84 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.15 | -1.5 | -1.43 | -2.79 | -2.84 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.15 | -1.5 | -1.43 | -2.79 | -2.84 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.009 | -0.012 | -0.01 | -0.018 | -0.017 |